Early access
Sign in
Active, not recruitingNo phase

Evaluation of the Viability and Safety of Early Discharge Protocol After TAVI Implantation

Key facts

Who runs it
Fundación EPIC
Where
Spain13 sites in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
585 people, planned
Started
4 Apr 2023
Expected to end
1 Dec 2026
Type of study
Observational
Treatments tested
  • TF TAVI
Record updated
19 December 2025

Who can take part

Age
18 years and older
Sex
Women and men

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Patients who meet all of the following conditions will be included:
  • Patients ≥ 18 years undergoing transfemoral TAVI implantation scheduled, performed on an outpatient basis
  • Patients with percutaneous implant
  • Patients undergoing the procedure under superficial sedation or Local anesthesia
  • Patients with baseline narrow QRS that does not change after implantation, or definitive pacemaker carrier
  • Patients who have signed the informed consent

Who cannot take part

  • Patients who do not meet any of the following conditions:
  • Patients with a wide QRS (greater than or equal to 120 msec) at baseline, with the except for patients with permanent pacemakers
  • Hospitalized patients undergoing urgent TAVI implantation
  • Patients with access other than percutaneous transfemoral

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Evaluation of the safety and efficacy of early discharge (24 hours) after transfemoral transcatheter aortic prosthesis implantation (TAVI).

The group in the trial

  • Patients receiving transfemoral (TF) TAVI

    TF TAVI

    Treatment: TF TAVI

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Record updated
19 December 2025